Shopping Cart (0)
My Account

Shopping Cart
SELECTBIO Conferences Exosomes & Single Cell Analysis Summit

Johan Skog's Biography

Johan Skog, Chief Scientific Officer, Exosome Diagnostics Inc

Dr. Skog currently serves as chief scientific officer of Exosome Diagnostics where he is leading the research and development efforts for biofluid diagnostics using exosomes in diseases such as cancer, metabolic and neurodegenerative diseases. He is the primary inventor of Exosome Diagnostics' core technology and, in particular, blood-based genetic diagnostics of cancer. Dr. Skog made the discovery that tumor-shed exosomes (microvesicles) contain genetic information of the tumor. He showed that these microvesicles serve to deliver messages to other cells inducing changes favorable to the proliferation of cancer cells. He demonstrated that these tumor exosomes are released into the bloodstream and that they can be isolated and studied for genetic mutations (Skog et al. Nature Cell Biology 2008; 10: 1470-1476). Prior to the start of the company Exosome Diagnostics, Dr. Skog was working at Massachusetts General Hospital/Harvard Medical School where he was studying the role of tumor stem cells in gliomas and later tumor derived exosomes, including their content of RNA biomarkers and transposable elements such as endogenous retroviruses. He also showed that gene therapy vectors can be incorporated into microvesicles and be used as a “stealth” vector with changed tropisms (Maguire et al. Molecular Therapy 2012 Feb 7). Dr. Skog received his PhD at the Department of Virology, Umea University, Sweden, working on novel gene therapy vectors for treatment of gliomas.

Johan Skog Image

How to Leverage the Power of Exosomes in Diagnostics

Friday, 19 September 2014 at 10:45

Add to Calendar ▼2014-09-19 10:45:002014-09-19 11:45:00Europe/LondonHow to Leverage the Power of Exosomes in DiagnosticsExosomes and Single Cell Analysis Summit in San Diego, California, USASan Diego, California,

Biofluid molecular diagnostics have generated a lot of interest the recent years, especially with new emerging platforms that enable low abundant tumor transcripts and mutations to be detected even from biobanked plasma and urine. Using biofluids as a surrogate for tissue to monitor the progression of disease processes is highly desirable for diseases like cancer where the genetic status of biopsies taken prior to treatment may not be relevant later in disease. The exosome platform allows for recovery of high quality nucleic acid for analysis of tumor derived mutations, splice-variants, and enables RNA profiling to stratify patients and monitor treatment efficacy on longitudinal samples. The latest data from Exosome Diagnostics improvements in detection methods of rare variants as well as improving the yield of tumor derived mutations from plasma will be presented.

Add to Calendar ▼2014-09-18 00:00:002014-09-19 00:00:00Europe/LondonExosomes and Single Cell Analysis SummitExosomes and Single Cell Analysis Summit in San Diego, California, USASan Diego, California,